TransMedics: 2027 Setting Up To Be A Pivotal Year

TransMedics Group is reiterated as a 'strong buy' due to compelling valuation and significant upside potential tied to multi-organ platform expansion. TMDX's 2027 catalysts include ENHANCE Heart, DENOVO Lung, CHOPS, OCS Kidney, and European expansion, all critical for achieving ambitious transplant volume targets. Q3 2026 saw record $203M revenue (+41% YoY), with management raising 2026 guidance to $764–$774M and operating margins expected at 12.5%–14%.